Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) to Ring The Nasdaq Stock Market Closing Bell
December 05 2016 - 10:00AM
What: Corbus Pharmaceuticals
Holdings, Inc. (NASDAQ:CRBP), a clinical stage drug
development company targeting rare, chronic, serious inflammatory
and fibrotic diseases will visit the Nasdaq MarketSite in Times
Square.
In honor of the occasion, Yuval Cohen, PhD,
Chief Executive Officer and Director, will ring the
Closing Bell.
Where: Nasdaq MarketSite – 4
Times Square – 43rd & Broadway – Broadcast Studio
When: Tuesday, December 6,
2016 – 3:45 p.m. to 4:00 p.m. ET
Corbus Contact:Jenene Thomas
CommunicationsJenene
Thomas908.996.0239jtc@jenenethomascommunications.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information: Fiber Line
(Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page: http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page: http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page: http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page: http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq
Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution
photograph of the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About Corbus Corbus Pharmaceuticals
Holdings, Inc. is a clinical stage pharmaceutical company focused
on the development and commercialization of novel therapeutics to
treat rare, chronic, and serious inflammatory and fibrotic
diseases. Our lead product candidate, JBT-101, is a novel synthetic
oral endocannabinoid-mimetic drug designed to resolve chronic
inflammation, and fibrotic processes. JBT-101 is currently in Phase
2 clinical studies for the treatment of cystic fibrosis, diffuse
cutaneous systemic sclerosis and skin-predominant dermatomyositis,
with a fourth Phase 2 trial in systemic lupus erythematosus planned
to commence during the first half of 2017.
For more information, please
visit www.CorbusPharma.com and connect with the Company
on Twitter, LinkedIn, Google+ and Facebook.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
provider of trading, clearing, exchange technology, listing,
information and public company services across six continents.
Through its diverse portfolio of solutions, Nasdaq enables
customers to plan, optimize and execute their business vision with
confidence, using proven technologies that provide transparency and
insight for navigating today's global capital markets. As the
creator of the world's first electronic stock market, its
technology powers more than 70 marketplaces in 50 countries, and 1
in 10 of the world's securities transactions. Nasdaq is home to
more than 3,700 listed companies with a market value of $10.0
trillion and approximately 18,000 corporate clients. To learn more,
visit: nasdaq.com/ambition or business.nasdaq.com
-NDAQA-
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Sep 2023 to Sep 2024